Hamppu vahvistaa luita

hamppu_ kirjoitti:

Uuden tutkimuksen mukaan synteettinen HU-308 vahvistaa luustoa ja estää mm. osteoporoosiin sairastumista. Luista on löytynyt kannabinoidireseptoreita, ja endokannabinoideja (jotka vaikuttavat samoihin reseptoreihin kuin hampun THC, ja HU-308, tarvitaan luiden vahvuuden säätelyyn. Joillakin yksilöillä luissa on poikkeuksellisen vähän kannabinoidireseptoreita, ja he ovat vaarassa sairastua osteoporoosiin, jos eivät käytä kannabista.


Tämä viesti olisi paremmin sopinut osteoporoosi-palstalle, mutta käsittämättömän pimeä suomi24:n natsitoimitus katsoi parhaaksi sensuroida sen.

--

Endocannabinoid System Prevents Osteoporosis

January 12, 2006 - Jerusalem, Israel

Jerusalem, Israel: The endocannabinoid system appears to play a major role in preserving bone density and preventing the onset of osteoporosis, according to preclinical trail data published in the current issue of the journal Proceedings of the National Academy of Sciences of the USA. Endocannabinoids are marijuana-like chemicals produced naturally in humans and animals that bind to the same receptors as do plant-derived cannabinoids such as THC.

Researchers at the Bone Laboratory of the Hebrew University in Jerusalem found a high number of cannabis receptors present in the bones of mice. Mice that lacked these receptors developed severe osteoporosis as they aged. Researchers reported that the administration of the synthetic cannabinoid HU-308 slowed the development of osteoporosis, stimulated bone building and reduced bone loss.

"These results demonstrate that the endocannabinoid system is essential for the maintenance of normal bone mass, . [and that the cannabinoid receptor] offers a molecular target for the diagnosis and treatment of osteoporosis," researchers concluded.

Osteoporosis is a degenerative skeletal disease characterized by a deterioration of bone tissue. Patients with osteoporosis are at risk for suffering multiple fractures and other serious disabilities.

Previous research on endocannabinoids and the endocannabinoid receptor system indicates that cannabinoids may play a role in maintaining homeostasis (metabolic equilibrium) in humans and other living organisms. Biological functions regulated by endocannabinoids include appetite, body temperature, blood pressure, reproductive activity, learning capacity, and motor coordination.

For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, "Peripheral cannabinoid receptor, CB2, regulates bone mass," is available in the January 10, 2006 edition of the Proceedings of the National Academy of Sciences of the USA. Abstracts of the study are available online at:
http://www.pnas.org/cgi/doi/10.1073/pnas.0504187103




MEDICAL SCIENCES
Peripheral cannabinoid receptor, CB2, regulates bone mass

Orr Ofek *, Meliha Karsak , Nathalie Leclerc , Meirav Fogel *, Baruch Frenkel , Karen Wright , Joseph Tam *, Malka Attar-Namdar *, Vardit Kram *, Esther Shohami ¶, Raphael Mechoulam ||, Andreas Zimmer , and Itai Bab *, **

*Bone Laboratory and Departments of ¶Pharmacology and ||Medicinal Chemistry and Natural Products, Hebrew University of Jerusalem, Jerusalem 91120, Israel; Department of Psychiatry, Life and Brain Center, University of Bonn, 53105 Bonn, Germany; Department of Orthopaedic Surgery, Institute for Genetic Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033; and Department of Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom

Edited by Hector F. DeLuca, University of Wisconsin, Madison, WI, and approved November 11, 2005 (received for review May 22, 2005)

The endogenous cannabinoids bind to and activate two G protein-coupled receptors, the predominantly central cannabinoid receptor type 1 (CB1) and peripheral cannabinoid receptor type 2 (CB2). Whereas CB1 mediates the cannabinoid psychotropic, analgesic, and orectic effects, CB2 has been implicated recently in the regulation of liver fibrosis and atherosclerosis. Here we show that CB2-deficient mice have a markedly accelerated age-related trabecular bone loss and cortical expansion, although cortical thickness remains unaltered. These changes are reminiscent of human osteoporosis and may result from differential regulation of trabecular and cortical bone remodeling. The CB2–/– phenotype is also characterized by increased activity of trabecular osteoblasts (bone-forming cells), increased osteoclast (the bone-resorbing cell) number, and a markedly decreased number of diaphyseal osteoblast precursors. CB2 is expressed in osteoblasts, osteocytes, and osteoclasts. A CB2-specific agonist that does not have any psychotropic effects enhances endocortical osteoblast number and activity and restrains trabecular osteoclastogenesis, apparently by inhibiting proliferation of osteoclast precursors and receptor activator of NF-B ligand expression in bone marrow-derived osteoblasts/stromal cells. The same agonist attenuates ovariectomy-induced bone loss and markedly stimulates cortical thickness through the respective suppression of osteoclast number and stimulation of endocortical bone formation. These results demonstrate that the endocannabinoid system is essential for the maintenance of normal bone mass by osteoblastic and osteoclastic CB2 signaling. Hence, CB2 offers a molecular target for the diagnosis and treatment of osteoporosis, the most prevalent degenerative disease in developed countries.

kirjoitti:

Anonyymi

Kirjoita kommentti

5000

Lähetä